Opinion

Video

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

Author(s):

Barbara Burtness, MD,Victoria M. Villaflor, MD

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Video content above is prompted by the following:

  • Is there a specific patient population that might benefit from this treatment?
  • Are there any external factors that may impact your treatment selection? Are you monitoring your patients for EBV titer?
Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
2 experts in this video
2 experts in this video
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Related Content
Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Epcoritamab Monotherapy in R/R CLL | Image Credit: © LASZLO – stock.adobe.com
December 8th 2024

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

NCCN Updates Guidelines for Nasopharyngeal Carcinoma
December 4th 2024

Toripalimab Plus Chemo Stands Alone as Preferred Frontline Regimen in Updated NCCN Guidelines for Advanced Nasopharyngeal Carcinoma

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024